APR 24, 2015 8:43 AM PDT

Majority of Lung Cancer Treatment Decisions Not Guided by Genetics: Survey

WRITTEN BY: Ilene Schneider
Despite the majority of newly diagnosed advanced non-small cell lung cancer (NSCLC) patients being tested for genetic mutations, a gap still exists for providing a personalized treatment plan for patients based on their cancer type and mutation subtype, according to a new international survey. About 60 percent of surveyed U.S. oncologists do not determine their treatment decisions based on EGFR mutation subtype, compared with 50 percent in Canada and 23 percent in Asia. The survey, sponsored by Boehringer Ingelheim, was recently presented as a late-breaking abstract in the ESMO-IASLC Best Abstracts session at the 2015 European Lung Cancer Conference in Geneva, Switzerland.
About 60 percent of surveyed U.S. oncologists do not determine their treatment decisions based on EGFR mutation subtype.
"It is extremely important for each person diagnosed with lung cancer to receive the most appropriate treatment based on his or her particular cancer," said Jennifer King, Director of Science and Research for Lung Cancer Alliance. "For some patients, this will mean receiving genetic testing at the time of diagnosis to allow doctors to develop a personalized treatment plan."

The survey showed that 26 percent of U.S. physicians decided on therapy for their patients with advanced NSCLC before their mutation test results were available, compared to 30 percent in Europe and 12 percent in Asia.

According to the surveyed doctors, the main reasons for not conducting genetic tests, aside from tumor histology, were insufficient tissue/uncertainty of sufficient tissue, poor performance status and test results taking too long to come back.

International guidelines, which are endorsed specifically in the U.S., recommend EGFR mutation testing should be performed at diagnosis of NSCLC and results should guide treatment decisions to ensure all patients receive appropriate therapy according to their specific cancer type. According to the survey, almost two-thirds of physicians across all 10 countries chose prolonging survival as the most important treatment goal in deciding first-line therapy in advanced NSCLC.

According to the survey, 77 percent of U.S. and European oncologists order EGFR mutation tests before starting first-line therapy, but Asian oncologists order tests more frequently at 92 percent. In the Asian community, lung cancer is the number one cause of cancer death. Among Asian patients diagnosed with NSCLC, approximately 50 percent have EGFR mutations compared to 10 to 15 percent of Caucasians. There are different types of EGFR mutations, the most common being exon 19 deletions (Del19) and the exon 21 (L858R) substitution.

"When a lung cancer diagnosis is made, it's important to receive a biomarker test to determine whether particular mutations like EGFR are present," said Edward Kim, M.D., with the Levine Cancer Institute, Carolinas HealthCare System in Charlotte, NC. "EGFR mutation status is a critical prognostic factor that many doctors use when determining the most appropriate treatment options for patients. One would not start a patient with breast cancer on treatment without knowing hormone receptor or HER-2 status. We must be diligent in testing appropriate patients for mutation status to offer the appropriate therapy."

Source: Boehringer Ingelheim Pharmaceuticals, Inc
About the Author
  • Ilene Schneider is the owner of Schneider the Writer, a firm that provides communications for health care, high technology and service enterprises. Her specialties include public relations, media relations, advertising, journalistic writing, editing, grant writing and corporate creativity consulting services. Prior to starting her own business in 1985, Ilene was editor of the Cleveland edition of TV Guide, associate editor of School Product News (Penton Publishing) and senior public relations representative at Beckman Instruments, Inc. She was profiled in a book, How to Open and Operate a Home-Based Writing Business and listed in Who's Who of American Women, Who's Who in Advertising and Who's Who in Media and Communications. She was the recipient of the Women in Communications, Inc. Clarion Award in advertising. A graduate of the University of Pennsylvania, Ilene and her family have lived in Irvine, California, since 1978.
You May Also Like
DEC 04, 2019
Cancer
DEC 04, 2019
Photon up-conversion for new cancer treatments
Scientists from the University of California, Riverside and The University of Texas at Austin have made a breakthrough in materials science that has signif...
DEC 23, 2019
Technology
DEC 23, 2019
Can Artifical Intelligence Detect Leukemia?
Artificial intelligence has always been a hot topic of discussion in the medical sciences with a whirlwind of applications. However, know the latest curios...
JAN 03, 2020
Drug Discovery & Development
JAN 03, 2020
New Drug Combo Reverses Breast Cancer
Researchers from Georgetown University have found that combining a drug used for epilepsy, bipolar disorder, and migraines with a drug used to ease blood p...
FEB 14, 2020
Immunology
FEB 14, 2020
Rewired natural killer cells show promising results in leukemia patients
Natural killer (NK) cells are a subset of white blood cells that are key players in the innate immune system, orchestrating host-rejection responses agains...
FEB 12, 2020
Genetics & Genomics
FEB 12, 2020
Vapers Have Epigenetic Alterations Like Those Seen in Smokers
The activity of genes can be altered with chemical tags that get added to the genome, so-called epigenetic modifications....
FEB 16, 2020
Cell & Molecular Biology
FEB 16, 2020
Growing Cells on Scaffolding as an Alternative to Animal Models
Researchers may have just made it easier for investigators to switch to an engineered model and replace their animal colonies with electrospun synthetics....
Loading Comments...